These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35583812)

  • 41. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.
    Jewell ML; McCauliffe DP
    J Am Acad Dermatol; 2000 Jun; 42(6):983-7. PubMed ID: 10827400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal use of antimalarials in treating cutaneous lupus erythematosus.
    Wozniacka A; McCauliffe DP
    Am J Clin Dermatol; 2005; 6(1):1-11. PubMed ID: 15675885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biological therapies in the treatment of cutaneous lupus erythematosus.
    Presto JK; Hejazi EZ; Werth VP
    Lupus; 2017 Feb; 26(2):115-118. PubMed ID: 27687023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cutaneous lupus erythematosus: The impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies.
    Fetter T; Wenzel J
    Exp Dermatol; 2020 Nov; 29(11):1123-1132. PubMed ID: 32633821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study].
    Lardet D; Martin S; Truchetet F; Cuny JF; Virion JM; Schmutz JL
    Rev Med Interne; 2004 Nov; 25(11):786-91. PubMed ID: 15501347
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating and skin biopsy-present cytokines related to the pathogenesis of cutaneous lupus erythematosus.
    Erazo-Martínez V; Tobón GJ; Cañas CA
    Autoimmun Rev; 2023 Feb; 22(2):103262. PubMed ID: 36563771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions.
    Ugarte A; Danza A; Ruiz-Irastorza G
    Curr Opin Rheumatol; 2018 Sep; 30(5):482-489. PubMed ID: 29870497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Tsakonas E; Joseph L; Esdaile JM; Choquette D; Senécal JL; Cividino A; Danoff D; Osterland CK; Yeadon C; Smith CD
    Lupus; 1998; 7(2):80-5. PubMed ID: 9541091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of whole blood hydroxychloroquine concentration with cutaneous lupus erythematosus and factors associated with it: First multicenter, cross-sectional analysis in Malaysia.
    Peh D; Wan Ahmad Kammal WSL; Beh PJ; Yong ACH; Tan WC; Lim AL; Thevarajah S; Stanslas J; How KN
    J Dermatol; 2022 May; 49(5):545-549. PubMed ID: 35067938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural history of disease activity and damage in patients with cutaneous lupus erythematosus.
    Ker KJ; Teske NM; Feng R; Chong BF; Werth VP
    J Am Acad Dermatol; 2018 Dec; 79(6):1053-1060.e3. PubMed ID: 29969701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus.
    Franz B; Fritzsching B; Riehl A; Oberle N; Klemke CD; Sykora J; Quick S; Stumpf C; Hartmann M; Enk A; Ruzicka T; Krammer PH; Suri-Payer E; Kuhn A
    Arthritis Rheum; 2007 Jun; 56(6):1910-20. PubMed ID: 17530636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
    Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
    Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus.
    Yang J; Yang X; Yang J; Li M
    J Rheumatol; 2018 Jun; 45(6):818-826. PubMed ID: 29545450
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.
    Niebel D; de Vos L; Fetter T; Brägelmann C; Wenzel J
    Am J Clin Dermatol; 2023 Jul; 24(4):521-540. PubMed ID: 37140884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.
    Al-Rawi H; Meggitt SJ; Williams FM; Wahie S
    Lupus; 2018 Apr; 27(5):847-852. PubMed ID: 28862574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anifrolumab for treatment of refractory cutaneous lupus erythematosus.
    Blum FR; Sampath AJ; Foulke GT
    Clin Exp Dermatol; 2022 Nov; 47(11):1998-2001. PubMed ID: 35844070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Antimalarials in lupus erythematosus treatment].
    Woźniacka A
    Przegl Lek; 2002; 59(3):179-82. PubMed ID: 12184034
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus.
    Robinson ES; Werth VP
    Cytokine; 2015 Jun; 73(2):326-34. PubMed ID: 25767072
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
    Feldmann R; Salomon D; Saurat JH
    Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antimalarial agents and lupus.
    Wallace DJ
    Rheum Dis Clin North Am; 1994 Feb; 20(1):243-63. PubMed ID: 8153401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.